<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03677141</url>
  </required_header>
  <id_info>
    <org_study_id>GO40515</org_study_id>
    <secondary_id>2018-001039-29</secondary_id>
    <nct_id>NCT03677141</nct_id>
  </id_info>
  <brief_title>A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma</brief_title>
  <official_title>A Phase Ib/II, Open-Label, Multicenter, Randomized, Controlled Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, pharmacokinetics, and preliminary efficacy of
      mosunetuzumab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone
      (M-CHOP) and, subsequently, in combination with cyclophosphamide, doxorubicin, and prednisone
      (CHP) plus polatuzumab vedotin (CHP-pola) in participants with relapsed or refractory (R/R)
      B-cell non-Hodgkin lymphoma (NHL), and in previously untreated participants with diffuse
      large B-cell lymphoma (DLBCL).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 8, 2019</start_date>
  <completion_date type="Anticipated">June 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 22, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events (AE)</measure>
    <time_frame>Baseline through approximately 90 days after the last study treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete Response (CR) Rate at the Time of Primary Response Assessment Based on Positron Emission Tomography - Computed Tomography (PET-CT) as Assessed According to Lugano 2014 Response Criteria</measure>
    <time_frame>Approximately 6-8 weeks after Cycle 6 (cycle = 21 days), or at early treatment discontinuation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration (Cmax) of Mosunetuzumab</measure>
    <time_frame>At pre-defined intervals from Cycle 1, Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Serum Concentration (Cmin) of Mosunetuzumab</measure>
    <time_frame>At pre-defined intervals from Cycle 1, Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) of Mosunetuzumab</measure>
    <time_frame>At pre-defined intervals from Cycle 1, Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of Mosunetuzumab</measure>
    <time_frame>At pre-defined intervals from Cycle 1, Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vss) of Mosunetuzumab</measure>
    <time_frame>At pre-defined intervals from Cycle 1, Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Polatuzumab Vedotin</measure>
    <time_frame>At pre-defined intervals from Cycle 1, Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Plasma Concentration (Cmin) of Polatuzumab Vedotin</measure>
    <time_frame>At pre-defined intervals from Cycle 1, Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of Polatuzumab Vedotin</measure>
    <time_frame>At pre-defined intervals from Cycle 1, Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL of Polatuzumab Vedotin</measure>
    <time_frame>At pre-defined intervals from Cycle 1, Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vss of Polatuzumab Vedotin</measure>
    <time_frame>At pre-defined intervals from Cycle 1, Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Objective Response Rate (ORR), Defined as Complete Response (CR) or Partial Response (PR) at any Time on Study Based on PET-CT and/or CT scan as Assessed According to Lugano 2014 Response Criteria</measure>
    <time_frame>Baseline through 2 years after partial response assessment (PRA) (up to a total of approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>From the first occurrence of a response to disease progression, relapse, or death, whichever comes first (up to approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Drug Antibodies (ADAs) to Mosunetuzumab</measure>
    <time_frame>At pre-defined intervals from Cycle 1, Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADAs to Polatuzumab Vedotin</measure>
    <time_frame>At pre-defined intervals from Cycle 1, Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>From randomization to the first occurrence of disease progression, relapse, or death from any cause, whichever occurs first (up to approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS at 1 Year</measure>
    <time_frame>Randomization to 1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-Free Survival (EFS)</measure>
    <time_frame>From randomization to the first occurrence of disease progression or relapse, initiation of new anti-lymphoma therapy (NALT), or death from any cause, whichever occurs first (up to approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration in the European Organization for Research and Treatment of Cancer Quality of Life - Core 30 Questionnaire (EORTC QLQ-C30) Physical Functioning and Fatigue</measure>
    <time_frame>From baseline through follow-up (up to approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration in the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) Subscale</measure>
    <time_frame>From baseline through follow-up (up to approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>B-cell Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Phase Ib: Mosunetuzumab (M)-CHOP Dose Finding</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive M-CHOP up to the phase II recommended dose (RP2D).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase Ib: M-CHP-Pola Dose-Finding</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive M-CHP-Pola up to the RP2D.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II: M-CHOP Previously Untreated (1L) DLBCL Safety Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with 1L DLBCL will receive mosunetuzumab at the RP2D in combination with CHOP.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II: M-CHP-Pola 1L DLBCL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with 1L DLBCL will receive M-CHP-Pola at a dose determined in the dose finding stage.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II: Rituxumab (R)-CHP-Pola 1L DLBCL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with 1L DLBCL will receive R-CHP-Pola at a dose determined in the dose finding stage.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II: M-CHOP 1L DLBCL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with 1L DLBCL will receive M-CHOP at a dose determined in the dose finding stage.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mosunetuzumab</intervention_name>
    <description>Participants will receive intravenous (IV) mosunetuzumab.</description>
    <arm_group_label>Phase II: M-CHOP 1L DLBCL</arm_group_label>
    <arm_group_label>Phase II: M-CHOP Previously Untreated (1L) DLBCL Safety Cohort</arm_group_label>
    <arm_group_label>Phase II: M-CHP-Pola 1L DLBCL</arm_group_label>
    <arm_group_label>Phase Ib: M-CHP-Pola Dose-Finding</arm_group_label>
    <arm_group_label>Phase Ib: Mosunetuzumab (M)-CHOP Dose Finding</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polatuzumab Vedotin</intervention_name>
    <description>Participants will receive polatuzumab vedotin via IV.</description>
    <arm_group_label>Phase II: M-CHP-Pola 1L DLBCL</arm_group_label>
    <arm_group_label>Phase II: Rituxumab (R)-CHP-Pola 1L DLBCL</arm_group_label>
    <arm_group_label>Phase Ib: M-CHP-Pola Dose-Finding</arm_group_label>
    <arm_group_label>Phase Ib: Mosunetuzumab (M)-CHOP Dose Finding</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituxumab</intervention_name>
    <description>Participants will receive rituxumab via IV.</description>
    <arm_group_label>Phase II: Rituxumab (R)-CHP-Pola 1L DLBCL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Participants will receive cyclophosphamide via IV.</description>
    <arm_group_label>Phase II: M-CHOP 1L DLBCL</arm_group_label>
    <arm_group_label>Phase II: M-CHOP Previously Untreated (1L) DLBCL Safety Cohort</arm_group_label>
    <arm_group_label>Phase II: M-CHP-Pola 1L DLBCL</arm_group_label>
    <arm_group_label>Phase II: Rituxumab (R)-CHP-Pola 1L DLBCL</arm_group_label>
    <arm_group_label>Phase Ib: M-CHP-Pola Dose-Finding</arm_group_label>
    <arm_group_label>Phase Ib: Mosunetuzumab (M)-CHOP Dose Finding</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Participants will receive doxorubicin via IV.</description>
    <arm_group_label>Phase II: M-CHOP 1L DLBCL</arm_group_label>
    <arm_group_label>Phase II: M-CHOP Previously Untreated (1L) DLBCL Safety Cohort</arm_group_label>
    <arm_group_label>Phase II: M-CHP-Pola 1L DLBCL</arm_group_label>
    <arm_group_label>Phase II: Rituxumab (R)-CHP-Pola 1L DLBCL</arm_group_label>
    <arm_group_label>Phase Ib: M-CHP-Pola Dose-Finding</arm_group_label>
    <arm_group_label>Phase Ib: Mosunetuzumab (M)-CHOP Dose Finding</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Participants will receive vincristine via IV.</description>
    <arm_group_label>Phase II: M-CHOP 1L DLBCL</arm_group_label>
    <arm_group_label>Phase II: M-CHOP Previously Untreated (1L) DLBCL Safety Cohort</arm_group_label>
    <arm_group_label>Phase Ib: Mosunetuzumab (M)-CHOP Dose Finding</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Participants will receive oral prednisone.</description>
    <arm_group_label>Phase II: M-CHOP 1L DLBCL</arm_group_label>
    <arm_group_label>Phase II: M-CHOP Previously Untreated (1L) DLBCL Safety Cohort</arm_group_label>
    <arm_group_label>Phase II: M-CHP-Pola 1L DLBCL</arm_group_label>
    <arm_group_label>Phase II: Rituxumab (R)-CHP-Pola 1L DLBCL</arm_group_label>
    <arm_group_label>Phase Ib: M-CHP-Pola Dose-Finding</arm_group_label>
    <arm_group_label>Phase Ib: Mosunetuzumab (M)-CHOP Dose Finding</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Participants will receive tocilizumab via IV.</description>
    <arm_group_label>Phase II: M-CHOP 1L DLBCL</arm_group_label>
    <arm_group_label>Phase II: M-CHOP Previously Untreated (1L) DLBCL Safety Cohort</arm_group_label>
    <arm_group_label>Phase II: M-CHP-Pola 1L DLBCL</arm_group_label>
    <arm_group_label>Phase Ib: M-CHP-Pola Dose-Finding</arm_group_label>
    <arm_group_label>Phase Ib: Mosunetuzumab (M)-CHOP Dose Finding</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Phase Ib and Phase II Portions

          -  At least one bi-dimensionally measurable nodal lesion, defined as &gt; 1.5 cm in its
             longest dimension, or one bi-dimensionally measurable extranodal lesion, defined as &gt;
             1.0 cm in its longest diameter

          -  Eastern Cooperative Oncology Group Performance Status of 0, 1, or 2

          -  Adequate hematologic function

        Inclusion Criteria for Phase Ib Portion

        Participants must also meet the following criteria for study entry into the Phase Ib
        portion:

          -  Histologically confirmed B-cell NHL according to the World Health Organization (WHO)
             2016 classification expected to express the cluster of differentiation-20 (CD20)
             antigen

          -  Relapsed or refractory (R/R) B-cell NHL after at least one prior systemic lymphoma
             therapy

          -  Treatment with at least one prior CD20-directed therapy

          -  Group B only: no prior treatment with polatuzumab vedotin

        Inclusion Criteria for Phase II Portion

        Participants must also meet the following criteria for study entry in the Phase II portion:

          -  Previously untreated, histologically confirmed DLBCL according to WHO 2016
             classification

          -  International Prognostic Index (IPI) score of 2−5

        Exclusion Criteria

          -  Prior treatment with mosunetuzumab

          -  Prior allogenic stem-cell transplant

          -  Current Grade &gt;1 peripheral neuropathy

          -  Participants with history of confirmed progressive multifocal leukoencephalopathy
             (PML)

          -  Known or suspected chronic active Epstein Barr virus (CAEBV), hepatitis B, hepatitis C
             (HCV), or Human Immunodeficiency Virus (HIV)

          -  Prior solid organ transplantation

          -  History of autoimmune disease

          -  Current or past history of central nervous system (CNS) lymphoma

          -  Current or past history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or
             neurodegenerative disease

          -  Significant cardiovascular disease or pulmonary disease

          -  Clinically significant history of liver disease

          -  Recent major surgery within 4 weeks before the start of C1D1, other than superficial
             lymph node biopsies for diagnosis

        Exclusion Criteria for Phase Ib Portion

        Participants who also meet any of the following criteria will be excluded from study entry
        in the Phase Ib portion:

          -  Prior treatment with chemotherapy, immunotherapy, and biologic therapy 4 weeks prior
             to C1D1

          -  Prior treatment with radiotherapy within 2 weeks prior to C1D1

          -  Adverse events from prior anti-cancer therapy resolved to ≤Grade 1 (with the exception
             of alopecia and anorexia)

          -  Prior treatment with &gt;250 mg/m^2 doxorubicin (or equivalent anthracycline dose)

        Exclusion Criteria for Phase II Portion

        Participants who also meet any of the following criteria will be excluded from study entry
        in the Phase II portion:

          -  Participants with transformed lymphoma

          -  Prior therapy for B-cell NHL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GO40515 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global.rochegenentechtrials@roche.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California; Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles (UCLA) - Hematology/Oncology Santa Monica</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404-2023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0934</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Scott and White Hospital; Cancer Center</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin, Inc.</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226-3596</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Salzburg, LKH; Univ.Klinik f. Innere Medizin III der PMU</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LKH Steyr</name>
      <address>
        <city>Steyr</city>
        <zip>4400</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Wien, Allgemeines Krankenhaus der Stadt Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hanusch-Krankenhaus</name>
      <address>
        <city>Wien</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Gyeongsangnam-do</city>
        <zip>50612</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Catala d´Oncologia Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Seville</city>
        <state>Sevilla</state>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>280146</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 11, 2018</study_first_submitted>
  <study_first_submitted_qc>September 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2018</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

